NCT01787123View on ClinicalTrials.gov

Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2013

Primary Completion Date

January 1, 2019

Study Completion Date

January 1, 2019

Conditions

Subarachnoid HemorrhageIntracranial AneurysmDelayed Cerebral IschemiaDelayed Ischemic Neurological Deficit

Interventions

DRUG

Intravenous Cerebrolysin

14-day course of intravenous Cerebrolysin started within 4 days of ictus

DRUG

Normal Saline

14-day course of intravenous normal saline started within 4 days of ictus

Trial Locations (1)

Unknown

Kwong Wah Hospital, Hong Kong

All Listed Sponsors

lead

Kwong Wah Hospital

OTHER

NCT01787123 - Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage | Biotech Hunter | Biotech Hunter